Norman H Jensen

US Patent:

6551614, Apr 22, 2003

Filed:

Mar 14, 2001

Appl. No.:

09/805635

Inventors:

David P. Jacobus - Princeton NJ
Norman P. Jensen - Princeton NJ

Assignee:

Jacobus Pharmaceutical Co., Inc. - Princeton NJ

International Classification:

H61K 948

US Classification:

424451, 424400, 424464, 424422, 514633, 514331, 514616, 514660

Abstract:

Compounds of the formulae are disclosed. A method of protecting subjects from infections caused by an organism of the group: Plasmodium sp. , Mycobacterium sp. , complex, and by administering to the subjects liable to infections, a prophylactically effective amount of a compound of the foregoing formulae; and a method of reducing the level of infection in subjects caused by the above-listed organism by administering to the subjects an infection reductively effective amount of a compound of the foregoing formulae are also disclosed.

US Patent:

6693217, Feb 17, 2004

Filed:

Jan 30, 2003

Appl. No.:

10/354398

Inventors:

David P. Jacobus - Princeton NJ
Norman P. Jensen - Princeton NJ

Assignee:

Jacobus Pharmaceutical Co., Inc. - Princeton NJ

International Classification:

C07C27700

US Classification:

564234, 514633, 514635, 564229

Abstract:

Compounds of the formulae are disclosed. A method of protecting subjects from infections caused by an organism of the group: Plasmodium sp. Mycobacterium sp. , and by administering to the subjects liable to infections, a prophylactically effective amount of a compound of the foregoing formulae; and a method of reducing the level of infection in subjects caused by the above-listed organism by administering to the subjects an infection reductively effective amount of a compound of the foregoing formulae are also disclosed.

US Patent:

7256218, Aug 14, 2007

Filed:

Nov 18, 2003

Appl. No.:

10/716283

Inventors:

David P. Jacobus - Princeton NJ, US
Guy A. Schiehser - Washington Crossing PA, US
Hong-Ming Shieh - Newtown PA, US
Norman P. Jensen - San Rafael CA, US
Jacek Terpinski - North Brunswick NJ, US

Assignee:

Jacobus Pharmaceutical Company, Inc. - Princeton NJ

International Classification:

C07C 279/26
A61K 31/155
A61P 33/02
A61P 33/08
C07D 317/14
C07D 319/14
A61K 31/357
A61K 31/36

US Classification:

514633, 514635, 514452, 514464, 556233, 556234, 556235, 549365, 549462

Abstract:

Biguanide and dihydrotriazine derivatives, preferably substituted asymmetrical imidodicarbonimidic diamides derived from hydroxylamines, and compositions containing biguanide and dihydrotriazine derivatives are disclosed. In addition, methods of using the biguanide and dihydrotriazine derivatives, inter alia, as antimicrobial agents and methods of using the dihydrotriazine derivatives in biological assays are disclosed. Methods of making the biguanide and dihydrotriazine derivatives are also disclosed.

US Patent:

7563792, Jul 21, 2009

Filed:

Jun 27, 2007

Appl. No.:

11/769527

Inventors:

David P. Jacobus - Princeton NJ, US
Guy A. Schiehser - Washington Crossing PA, US
Hong-Ming Shieh - Newtown PA, US
Norman P. Jensen - San Rafael CA, US
Jacek Terpinski - North Brunswick NJ, US

Assignee:

Jacobus Pharmaceutical Company, Inc. - Princeton NJ

International Classification:

C07D 251/10
A61K 31/53
A61P 33/02
A61P 33/08
A61P 31/06

US Classification:

514246, 544204, 544205, 544206, 544207

Abstract:

Biguanide and dihydrotriazine derivatives, preferably substituted asymmetrical imidodicarbonimidic diamides derived from hydroxylamines, and compositions containing biguanide and dihydrotriazine derivatives are disclosed. In addition, methods of using the biguanide and dihydrotriazine derivatives, inter alia, as antimicrobial agents and methods of using the dihydrotriazine derivatives in biological assays are disclosed. Methods of making the biguanide and dihydrotriazine derivatives are also disclosed.

US Patent:

40071901, Feb 8, 1977

Filed:

Jun 21, 1974

Appl. No.:

5/481622

Inventors:

Tsung-Ying Shen - Westfield NJ
Norman P. Jensen - Watchung NJ
Arthur F. Wagner - Princeton NJ

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07D40114

US Classification:

260268DK

Abstract:

Novel derivatives of 3,6-bis(2-piperidinyl)-2,5-piperazinedione and processes for preparing the same. The new compounds exhibit activity in inhibiting the growth of tumors in mammals and birds, and in inhibiting the growth of certain microorganisms.

US Patent:

40113264, Mar 8, 1977

Filed:

Jul 29, 1975

Appl. No.:

5/600169

Inventors:

Norman P. Jensen - New Providence NJ

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07D49804

US Classification:

424256

Abstract:

Oxazolo[4,5-b]pyridine substituted in the 2-position with a polyhydrobicycloaryl group are topical anti-inflammatory agents. They are prepared by condensing a 2-amino-3-hydroxypyridine with the appropriate carboxylic compound.

US Patent:

46862358, Aug 11, 1987

Filed:

Aug 12, 1985

Appl. No.:

6/764446

Inventors:

Michael N. Chang - Westfield NJ
Norman P. Jensen - Princeton NJ
Milton L. Hammond - Somerville NJ
Robert A. Zambias - Springfield NJ
John McDonald - Indianapolis IN
Kathleen M. Rupprecht - Cranford NJ

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07C 3921
A61K 3105

US Classification:

514520

Abstract:

Substituted cinnamyl-2,3-dihydrobenzofurans and analogs were prepared from the nucleophlic substitution of a cinnamylhalide with a 2,3-dihydrobenzofuran anion or an analog thereof. These compounds were found to be potent topical anti-inflammatory agents.

US Patent:

39324397, Jan 13, 1976

Filed:

May 28, 1974

Appl. No.:

5/473164

Inventors:

Norman P. Jensen - Watchung NJ

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07D26104

US Classification:

260307A

Abstract:

Stabilized cycloserine compositions, having enhanced stability, and effective in releasing cycloserine compounds in vivo, are prepared by reacting D-4-amino-3-isoxazolidinone or its 5-methyl derivative with 2,4-pentanedione or alkyl-substituted-2,4-pentanedione to form the corresponding N-substituted-cycloserine compound in which one of the hydrogens attached to the primary amino group is replaced by 1-methyl-3-oxo-1-butenyl or an alkyl substituted-1-methyl-3-oxo-1-butenyl grouping. These D-4-(1'-methyl-3'-oxo-1'-butenyl or alkyl-substituted-1'-methyl-3'-oxo-1'-butenyl)amino-3-isoxazolidinones or 5-methyl derivative thereof, which may also be referred to as N-(1-methyl-3-oxo-1-butenyl or alkyl-substituted-1-methyl-3-oxo-1-butenyl)-derivative of cycloserine or methyl-cycloserine, as well as their pharmacologically acceptable salts, are remarkably stable on storage as well as upon oral administration, and are extremely effective in releasing in vivo the cycloserine compound containing the free primary amino grouping.